$ABBV

AbbVie Inc.

CIK:0001551152|SEC Filings
v3.25.4
Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]      
Net revenues $ 61,160 $ 56,334 $ 54,318
Cost of products sold 18,204 16,904 20,415
Selling, general and administrative 14,010 14,752 12,872
Research and development 9,096 12,791 7,675
Acquired IPR&D and milestones 5,016 2,757 778
Other operating income (241) (7) (179)
Total operating costs and expenses 46,085 47,197 41,561
Operating earnings 15,075 9,137 12,757
Interest expense, net 2,627 2,160 1,684
Net foreign exchange loss 58 21 146
Other expense, net 5,793 3,240 4,677
Earnings before income tax expense 6,597 3,716 6,250
Income tax expense (benefit) 2,364 (570) 1,377
Net earnings 4,233 4,286 4,873
Net earnings attributable to noncontrolling interest 7 8 10
Net earnings attributable to AbbVie Inc. $ 4,226 $ 4,278 $ 4,863
Per share data      
Basic earnings per share (in dollars per share) $ 2.37 $ 2.40 $ 2.73
Diluted earnings per share (in dollars per share) $ 2.36 $ 2.39 $ 2.72
Weighted-average basic shares outstanding (in shares) 1,769 1,769 1,768
Weighted-average diluted shares outstanding (in shares) 1,773 1,773 1,773